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CASE REPORT
The first patient, a 63-year-old Dutch male living in the
south of The Netherlands, presented at a regional hospital with
dyspnea and a productive cough. No fever, malaise, hemopty-
sis, night sweats, or weight loss was reported. His medical
history included chronic obstructive pulmonary disease. Since
a chest X ray revealed a single opacity in the right upper lobe,
computed tomography scanning (CT) was performed, demon-
strating calcification in a mediastinal lymph node and a solid
mass with spiculae in the right upper lobe, suggestive of ma-
lignancy. In the diagnostic workup, a bronchoalveolar lavage
was performed. No malignant cells were found in the cytology
sample of the lavage fluid. Although no acid-fast bacilli were
seen on direct microscopy, the routine mycobacterial culture of
the lavage fluid yielded Mycobacterium conspicuum. Serologi-
cal examination lowered the suspicion of an infectious process,
with an erythrocyte sedimentation rate of 5 mm/h and a white
blood cell count of 7.8 per nl. Although no malignancy was
cytologically proven, a mediastinoscopy was performed for
staging of the suspected malignancy. No evidence of either
malignancy or mycobacterial infection was found in the lymph
node samples. Based on the radiographic image and the me-
diastinoscopy result, the patient underwent a lobectomy of the
right upper lobe and a squamous cell carcinoma was diagnosed
histologically. No histological evidence of mycobacterial infec-
tion was found. Based on the single positive culture, nonsus-
pect radiographic image, and alternative diagnosis, the M. con-
spicuum isolate was considered a contaminant; hence, no
antimycobacterial treatment was started.
The second patient was a 65-year-old Dutch male from the
eastern part of The Netherlands whose medical history con-
sisted of radiographic stage IV sarcoidosis. His sarcoidosis was
not treated with immunosuppressive agents. The patient pre-
sented at another regional hospital with dyspnea and a pro-
ductive cough, without a fever, night sweats, weight loss, or
malaise. A chest X ray and CT revealed further progression of
preexistent interstitial nodular opacities, thick septa, bronchi-
ectasis, fibrotic scarring, bullae, emphysema, and a ground-
glass aspect. During the next 2 years, 13 mycobacterial sputum
cultures were performed, 10 of which yielded M. conspicuum;
3 cultures remained negative, although two samples were ini-
tially PCR positive for a nontuberculous mycobacterium
(NTM) identified as M. conspicuum by sequencing of the PCR
product. All acid-fast-bacillus smears were negative. The sero-
logical parameters of infection were slightly raised; the eryth-
rocyte sedimentation rate ranged between 21 and 32 mm/h, the
C-reactive protein concentration ranged between 13 and 44
mg/liter, and the white blood cell count was 12.2 per nl. The
disease progressed in these 2 years, with increasingly frequent
Pseudomonas aeruginosa infections and chronic hypoxia, mak-
ing the patient oxygen dependent. It was decided that the
sarcoidosis, rather than the M. conspicuum infection, would be
treated, and the patient underwent bilateral lung transplanta-
tion 2 years and 8 months after the first M. conspicuum culture.
The last sputum culture yielding M. conspicuum was per-
formed 8 weeks prior to transplantation. The patient died of
respiratory failure 17 days after transplantation; the donor
lungs were colonized by P. aeruginosa and an Acinetobacter
species. Autopsy revealed an acute necrotizing pneumonia in
both lungs, most likely caused by P. aeruginosa. The native
lungs were not examined.
Based on the progression of symptoms and radiographic
abnormalities as well as multiple positive cultures, this patient
met the American Thoracic Society (ATS) diagnostic criteria
(1) and thus was likely to have M. conspicuum pulmonary
disease. However, fulfillment of these criteria does not neces-
sitate treatment per se; this is a decision based on potential
risks and benefits of therapy for the individual patient (1). In
addition, the progression of symptoms and radiographic ab-
normalities may have been due to sarcoidosis alone. For these
reasons, no antimycobacterial treatment was initiated. Histo-
logical examination of the native lungs could have provided
additional proof of M. conspicuum infection. Previously, the
condition of persistent culture positivity with little or no clin-
ical or radiographic deterioration has been referred to as col-
onization. However, airway colonization without infection is an
unproven condition for NTM and recent studies with high-
resolution CT, summarized in the ATS statement, have re-
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vealed progressive nodular bronchiectatic disease, as in our
patient, considered to be due to NTM (1).
Since its isolation and subsequent description as a novel
Mycobacterium species in 1995 by Springer et al., no reports on
clinical M. conspicuum isolation have been recorded in the
literature (2). Mycobacterium conspicuum is a rare clinical iso-
late phylogenetically most closely related to Mycobacterium
malmoense and Mycobacterium szulgai on the basis of 16S
rRNA gene sequences (2).
In our country, over an 8-year period, bacteria of this species
have been isolated only from the pulmonary samples of the two
patients presented. The mycobacteria were cultured in the
MB/BacT system (Biomerieux, Boxtel, The Netherlands) as
well as on Middlebrook 7H10, Ogawa, and Coletsos-T (Bio-
Merieux) solid media at 35°C. Growth was observed after 13
days in the MB/BacT liquid medium and after 28 to 35 days on
the solid media. No growth was observed after 35 days on
Lo¨wenstein-Jensen media with or without pyruvate incubated
at 35°C. On Middlebrook 7H10 media, colonies were small,
smooth, and white.
Identification was performed at the Dutch national myco-
bacteria reference laboratory (RIVM) by sequencing of the
151-bp hypervariable region in the 16S rRNA gene after ruling
out the M. tuberculosis complex by using the Hain GenoType
M. tuberculosis complex (Hain Lifesciences GmbH, Nehren,
Germany) line probe assay and the more common species of
NTM by using the INNO-LiPA MYCOBACTERIA v2 (Inno-
genetics, Ghent, Belgium) reverse line blot assay. The obtained
sequences were compared to those in the Ribosomal Differ-
entiation of Medical Microorganisms database (http://rdna
.ridom.de). All isolates from patient 2 were also identified as
M. conspicuum in the regional hospital laboratory by 16S gene
sequence analysis.
We performed drug susceptibility testing for four M. con-
spicuum isolates (one from patient 1 and three from patient 2),
using a previously published Middlebrook 7H10 agar dilution
method (3). The drugs included in the panel, with their break-
point concentrations in parentheses, are isoniazid (1 g/ml),
rifampin (1 g/ml), ethambutol (5 g/ml), streptomycin (5
g/ml), cycloserine (50 g/ml), prothionamide (5 g/ml), ami-
kacin (5 g/ml), ciprofloxacin (2 g/ml), clofazimine (2 g/ml),
clarithromycin (16 g/ml), and rifabutin (2 g/ml). Growth at
the breakpoint concentration is reported as susceptible, and
growth at higher concentrations of the drug is considered re-
sistant. The results are detailed in Table 1.
The original species description featured two immunocom-
promised patients suffering from disseminated infections (1,
2). The patients presented here were not known to suffer from
impaired systemic immunity, but their preexisting pulmonary
diseases predisposed them to NTM infection. For patient 1,
follow-up cultures in the 3 years since M. conspicuum isolation
have yielded other NTM (one Mycobacterium avium and one
Mycobacterium kansasii isolate), indicative of increased suscep-
tibility to mycobacterial infections in general. The demograph-
ics, with the patients being male, white, and older than the
average tuberculosis patient, are common for NTM infections
and probably reflect the characteristics of the predisposing
lung disease.
To assess the clinical relevance of M. conspicuum isolation
from these patients, we used the diagnostic criteria set in the
recent ATS statement (1). Although these criteria fit best with
the M. avium complex, M. kansasii, and Mycobacterium absces-
sus, the authors state that “it is assumed, but not proven, that
the concepts outlined in these guidelines are pertinent for
other less common NTM respiratory pathogens” (1).
Our findings indicate that M. conspicuum is not only a caus-
ative agent of disseminated infections in immunocompromised
patients. This species may occasionally cause pulmonary infec-
tions in immunocompetent persons with preexisting pulmonary
diseases or be a mere contaminant. This is in line with what has
been found for most other NTM species (1).
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TABLE 1. In vitro drug susceptibility results for four
Mycobacterium conspicuum strains
Drug
MIC (mg/liter) for indicated isolate
Overall status
No. 1a No. 2b No. 3b No. 4b
Isoniazid 10 2 5 5 Resistant
Rifampin 5 5 5 5 Resistant
Rifabutin 0.5 0.5 0.5 0.5 Susceptible
Ethambutol 5 1 2 2 Susceptible
Streptomycin 10 5 5–10 5 Variable
Amikacin 10 10 20 10 Resistant
Clarithromycin 2 2 2 2 Susceptible
Ciprofloxacin 1 1 1 1 Susceptible
Cycloserine 10 10 10 10 Susceptible
Prothionamide 5 5 5 2 Susceptible
Clofazimine 2 0.5 1 1 Susceptible
a Isolate from patient 1.
b Isolate from patient 2.
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